UBS Group’s NextCure NXTC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $951 | Buy |
594
+256
| +76% | +$1.89K | ﹤0.01% | 9685 |
|
|
2026
Q1 | $3.61K | Hold |
338
| – | – | ﹤0.01% | 9058 |
|
|
2025
Q4 | $4.8K | Sell |
338
-263
| -44% | -$2.73K | ﹤0.01% | 8778 |
|
|
2025
Q3 | $3.52K | Sell |
601
-424
| -41% | -$2.22K | ﹤0.01% | 9037 |
|
|
2025
Q2 | $5.66K | Buy |
1,025
+314
| +44% | +$1.69K | ﹤0.01% | 9151 |
|
|
2025
Q1 | $4.1K | Buy |
711
+361
| +103% | +$3.18K | ﹤0.01% | 9146 |
|
|
2024
Q4 | $3.24K | Sell |
350
-106
| -23% | -$1.56K | ﹤0.01% | 8906 |
|
|
2024
Q3 | $7.49K | Sell |
456
-371
| -45% | -$6.83K | ﹤0.01% | 7901 |
|
|
2024
Q2 | $15.8K | Sell |
827
-74
| -8% | -$1.44K | ﹤0.01% | 7457 |
|
|
2024
Q1 | $24.1K | Buy |
901
+379
| +73% | +$6.53K | ﹤0.01% | 6837 |
|
|
2023
Q4 | $7.14K | Sell |
522
-453
| -46% | -$6.57K | ﹤0.01% | 7644 |
|
|
2023
Q3 | $15.1K | Sell |
975
-330
| -25% | -$6.3K | ﹤0.01% | 6939 |
|
|
2023
Q2 | $28.2K | Buy |
1,305
+244
| +23% | +$4.8K | ﹤0.01% | 6743 |
|
|
2023
Q1 | $18.9K | Buy |
1,061
+175
| +20% | +$3.37K | ﹤0.01% | 7128 |
|
|
2022
Q4 | $15K | Buy |
886
+55
| +7% | +$1.26K | ﹤0.01% | 8022 |
|
|
2022
Q3 | $27K | Buy |
831
+54
| +7% | +$2.75K | ﹤0.01% | 7006 |
|
|
2022
Q2 | $44K | Buy |
777
+14
| +2% | +$731 | ﹤0.01% | 6021 |
|
|
2022
Q1 | $45K | Buy |
763
+528
| +225% | +$33K | ﹤0.01% | 6605 |
|
|
2021
Q4 | $17K | Buy |
235
+232
| +7,733% | +$19.4K | ﹤0.01% | 8071 |
|
|
2021
Q3 | $0 | Buy |
3
+1
| +50% | +$88 | ﹤0.01% | 9910 |
|
|
2021
Q2 | $0 | Sell |
2
-175
| -99% | -$17.9K | ﹤0.01% | 9672 |
|
|
2021
Q1 | $21K | Sell |
177
-467
| -73% | -$67.6K | ﹤0.01% | 7339 |
|
|
2020
Q4 | $84K | Buy |
644
+640
| +16,000% | +$82.7K | ﹤0.01% | 5801 |
|
|
2020
Q3 | $0 | Buy |
+4
| New | +$492 | ﹤0.01% | 8281 |
|
|
2020
Q2 | – | Sell |
-763
| Closed | -$339K | – | 8238 |
|
|
2020
Q1 | $339K | Buy |
763
+717
| +1,559% | +$383K | ﹤0.01% | 4309 |
|
|
2019
Q4 | $31K | Sell |
46
-158
| -77% | -$79.3K | ﹤0.01% | 6618 |
|
|
2019
Q3 | $75K | Buy |
204
+84
| +70% | +$27.3K | ﹤0.01% | 5942 |
|
|
2019
Q2 | $22K | Buy |
+120
| New | +$24.9K | ﹤0.01% | 6547 |
|
Other funds holding NXTC
IC
SI
BFM
SCM
VA
P
UBS Group's NXTC Position: Q2 2026 in Review
UBS Group increased its NextCure (NXTC) stake by 76% in Q2 2026, buying an estimated $1.89K and bringing the position to 594 shares worth $951. The position accounts for ﹤0.01% of the portfolio, ranked #9685.
UBS Group first reported a position in NXTC in Q2 2019 and has held it in 28 quarters since. The position peaked at $339K in Q1 2020. 30 funds tracked by Wall St. Rank hold NXTC as of Q2 2026.
- UBS Group held 594 shares of NextCure worth $951 as of Q2 2026.
- UBS Group bought 256 NextCure shares in Q2 2026, an estimated $1.89K.
- NextCure made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9685 holding.
- UBS Group first reported a position in NextCure in Q2 2019 and has held it in 28 quarters since.
- UBS Group's NextCure position peaked at $339K in Q1 2020.
- 30 funds tracked by Wall St. Rank held NextCure as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.